| Size | Price | |
|---|---|---|
| 1mg | ||
| Other Sizes |
Purity: ≥98%
5Z-7-Oxozeaenol, a natural anti-protozoan compound isolated from fungae, is a novel, potent irreversible / covalent and selective inhibitor of TAK1 and VEGF-R2 with IC50s of 8 nM and 52 nM, respectively.
| ln Vitro |
5Z-7-Oxozeaenol exhibits strong, irreversible, and specific inhibition of TGF-β-activated kinase 1 (TAK1, IC50, 8.1 nM), while demonstrating negligible effect against MEK1 (IC50, 411 nM). By blocking TAK1 MAPK kinase kinase's catalytic activity, 5Z-7-Oxozeaenol reduces inflammation [1]. Moreover, 5Z-7-Oxozeaenol inhibits VEGF-R2 with an IC50 of 52 nM. 5Z-7-Oxozeaenol exhibits inhibitory activity with IC50 values of 110, 170, 340, 6300, and 6600 nM, respectively, against VEGF-R3, FLT3, PDGFR-β, B-RAF VE, and SRC [2]. Although 5Z-7-Oxozeaenol is a signaling-specific inhibitor rather than a direct inhibitor, it nevertheless inhibits the JNK/p38 pathway. 5Z-7-Oxozeaenol has no effect on IL-1-induced NF-kB activity in KK cells, but it reduces PMA-induced AP-1 activity in KT cells to nearly basal levels [3].
|
|---|---|
| References |
|
| Additional Infomation |
5Z-7-oxozeaenol is a macrolide that is the 7-oxo derivative of zeaenol (the 5Z stereoisomer). Isolated from Fungi, it exhibits cytotoxic, antibacterial and inhibitory activity against NF-kappaB. It has a role as a metabolite, an antibacterial agent, an antineoplastic agent and a NF-kappaB inhibitor. It is an aromatic ether, a macrolide, a member of phenols, a secondary alcohol and a secondary alpha-hydroxy ketone.
5Z-7-Oxozeaenol has been reported in Curvularia lunata with data available. |
| Molecular Formula |
C19H22O7
|
|---|---|
| Molecular Weight |
362.37378
|
| Exact Mass |
362.137
|
| CAS # |
253863-19-3
|
| PubChem CID |
9863776
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
556
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
C[C@H]1C/C=C\C(=O)[C@H]([C@H](C/C=C/C2=C(C(=CC(=C2)OC)O)C(=O)O1)O)O
|
| InChi Key |
NEQZWEXWOFPKOT-BYRRXHGESA-N
|
| InChi Code |
InChI=1S/C19H22O7/c1-11-5-3-7-14(20)18(23)15(21)8-4-6-12-9-13(25-2)10-16(22)17(12)19(24)26-11/h3-4,6-7,9-11,15,18,21-23H,5,8H2,1-2H3/b6-4+,7-3-/t11-,15-,18+/m0/s1
|
| Chemical Name |
(3S,5Z,8S,9S,11E)-3,4,9,10-Tetrahydro-8,9,16-trihydroxy-14-methoxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione
|
| Synonyms |
FR-148083; L-783279; LL-Z 1640-2; FR148083; L783279; LL-Z 1640-2; 5Z-7-Oxozeaenol; 5Z 7 Oxozeaenol; 5Z7Oxozeaenol; 5-Z-7-Oxozeaenol; 5 Z 7 Oxozeaenol; 5Z7O; L-783279; 5 Z 7 O; L 783279; 5-Z-7-O; L783279; (5Z)-7-Oxozeaenol;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~137.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.90 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.90 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.90 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7596 mL | 13.7981 mL | 27.5961 mL | |
| 5 mM | 0.5519 mL | 2.7596 mL | 5.5192 mL | |
| 10 mM | 0.2760 mL | 1.3798 mL | 2.7596 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA